March 19 (Reuters) - Fusion Pharmaceuticals Inc ( FUSN )

:

* FUSION PHARMACEUTICALS TO BE ACQUIRED BY ASTRAZENECA,

ACCELERATING DEVELOPMENT OF NEXT-GENERATION RADIOCONJUGATES TO

TREAT CANCER

* REPRESENTING A TOTAL TRANSACTION VALUE OF APPROXIMATELY

$2.4

BILLION INCLUDING CVR

* SHAREHOLDERS TO RECEIVE $21.00 PER SHARE IN CASH AT

CLOSING PLUS

A NON-TRANSFERRABLE CVR OF $3.00 PER SHARE

* UPFRONT CASH PORTION OF CONSIDERATION REPRESENTS A

TRANSACTION

VALUE OF APPROXIMATELY $2 BILLION

* FUSION WILL BECOME A WHOLLY OWNED SUBSIDIARY OF

ASTRAZENECA,

WITH OPERATIONS CONTINUING IN CANADA AND US

Source text for Eikon:

Further company coverage: